Levels of cytokines and thyroid autoantibodies in Omani patients with Graves’ disease

References

• Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 227–57.
   Google Scholar
• Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787–93.
   Google Scholar
• Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 263–6.
   Google Scholar
• Collins J, Gough S. Autoimmunity in thyroid disease. Eur J Nucl Med Mol Imaging 2002; 29 (Suppl 2): S417–24.
   Google Scholar
• Tonacchera M, van Sande J, Parma J et al. TSH receptor and disease. Clin Endocrinol (Oxf) 1996; 44: 621–33.
   Google Scholar
• Rapoport B, Chazenbalk GD, Jaume JC, McLachlan SM. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998; 19: 673–716.
   Google Scholar
• Arqueros MC, el Tamer E, el Tamer S, Houssay AB. TSH receptor antibodies as a recurrence index of Graves’ disease treated with antithyroid drugs (Spanish). Medicina (B Aires) 1991; 51: 9–13.
   Google Scholar
• Weetman AP, Aijan RA, Watson PF. Cytokines and Graves’ disease. Bailliere’s Clin Endocrinol Metab 1997; 11: 481–97.
   Google Scholar
• Ward LS, Fernandes GA. Serum cytokine levels in autoimmune and non-autoimmune hyperthyroid states. Braz J Med Biol Res 2000; 33: 65–9.
   Google Scholar
• Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto’s thyroiditis (Th1) and Graves’ disease (Th2). Neuroimmunomodulation 2004; 11 (4): 209–13.
   Google Scholar
• Al-Humaidi MA. Serum cytokine levels in Graves’ disease. Saudi Med J 2000; 21: 639–44.
   Google Scholar
• Bossowski A, Urban M. Serum levels of cytokines in children and adolescents with Graves’ disease and non-toxic goiter J Pediatr Endocrinol Metab 2001; 14: 741–7.
   Google Scholar
• Nawroth PP, Banks I, Handley D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1986; 163: 1363–75.
   Google Scholar
• Bonavida B, Paubert M, Hosford D. The involvement of plateletactivating factor (PAF)-induced monocyte activation and tumor necrosis factor production in shock. Prog Clin Biol Res 1989; 308: 485–9.
   Google Scholar
• Heuer M, Aust G, Ode-Hakim S, Scherbaum WA. Different cytokine profiles in Graves’ disease, Hashimoto’s thyroiditis and non-autoimmune thyroid disorders determined by quantitative reverse transcriptase polymerase chain reaction (RT-PCR). Thyroid 1996; 6: 97–106.
   Google Scholar
• McLachlan SM, Taverne J, Atherton MC. Cytokines, thyroid autoantibody synthesis and thyroid cell survival in culture. Clin Exp Immunol 1990; 79: 175–81.
   Google Scholar
• Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145–73.
   Google Scholar
• Feldmann M, Brennan FM, Chantry D et al. Cytokine assays: role in evaluation of the pathogenesis of autoimmunity. Immunol Rev 1991; 119: 105–23.
   Google Scholar
• Feldt-Rasmussen U, Schleusenter H, Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long-term remission after medical therapy of Graves’ disease. J Clin Endocrinol Metab 1994; 78: 98–102.
   Google Scholar
• Mankai A, Toumi D, Chadli-Chaieb M et al. Antithyroid-stimulating hormone receptor antibodies determined by second-generation assay. Clin Chem Lab Med 2007; 45: 26–9.
   Google Scholar
• Feldt-Rasmussen U, Bech K, Date J, Petersen PH, Johansen K, Madsen SN. Thyroid stimulating antibodies, thyroglobulin antibodies and serum proteins during antithyroid treatment with radioiodine or propylthiouracil of Graves’ disease. Allergy 1982; 32: 161–72.
   Google Scholar
• Takamatsu J, Hosoya T, Kohno Y et al. Changes in serum autoantibodies to thyroid peroxidase during antithyroid drug therapy for Graves’ disease. Endocrinol Jpn 1990; 37: 275–83.
   Google Scholar